FDG-PET-Adapted Sequential Therapy with Brentuximab Vedotin and Augmented ICE Followed by ASCT for Relapsed/Refractory HL


FDG-PET-Adapted Sequential Therapy with Brentuximab Vedotin and Augmented ICE Followed by ASCT for Relapsed/Refractory HL
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Craig Moskowitz, MD (7/17/13)
Moskowitz A et al. FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous cell transplant for relapsed and refractory Hodgkin lymphoma. Proc ASH 2013;Abstract 2099.

Dr Moskowitz is Clinical Director of the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center and Professor of Medicine at Weill Medical College of Cornell University in New York, New York.